Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023 08:15 ET
|
Royalty Pharma plc
NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 44th Annual Global Healthcare Conference on June...
Royalty Pharma Reports First Quarter 2023 Results
May 09, 2023 07:00 ET
|
Royalty Pharma plc
Net cash provided by operating activities (GAAP) of $1,034 million and Adjusted Cash Receipts(1) (non-GAAP) of $1,131 millionAnnounced transactions of up to $1.6 billion in Q1 2023, including $600...
Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference
May 03, 2023 16:15 ET
|
Royalty Pharma plc
NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10,...
Royalty Pharma Declares Second Quarter 2023 Dividend
April 17, 2023 08:15 ET
|
Royalty Pharma plc
NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2023 of $0.20 per Class A...
Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023
April 13, 2023 09:01 ET
|
Royalty Pharma plc
NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023 before the U.S....
Royalty Pharma Announces $1.0 Billion Share Repurchase Program
March 27, 2023 07:30 ET
|
Royalty Pharma plc
Royalty Pharma’s founder and Chief Executive Officer, Pablo Legorreta, has also indicated that he intends to purchase up to an additional $50 million of the company’s Class A ordinary shares NEW...
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
March 23, 2023 07:00 ET
|
Royalty Pharma plc
Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholdsPureTech retains...
Royalty Pharma Raises Full Year 2023 Guidance
March 15, 2023 08:00 ET
|
Royalty Pharma plc
Royalty Pharma now expects 2023 Adjusted Cash Receipts(1) (non-GAAP) to be between $2,850 million and $2,950 million, excluding contributions from future transactions NEW YORK, March 15, 2023 ...
Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments
March 01, 2023 08:15 ET
|
Royalty Pharma plc
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Ashwin Pai, M.D. as Executive Vice President, Investments. Ashwin will join Royalty...
Royalty Pharma Reports Q4 and Full Year 2022 Results
February 15, 2023 07:00 ET
|
Royalty Pharma plc
Net cash provided by operating activities (GAAP) of $570 million and Adjusted Cash Receipts(1) (non-GAAP) of $1,064 million in Q4 2022Announced transactions of up to $3.5 billion in 2022, including...